Shilpa CDMO Invests $50 Million to Expand Peptide Manufacturing Capacity in India
Why the pharmaceutical CDMO India segment is racing into peptides: Shilpa’s $50 million plan, what is set for December 2026 and what is undisclosed.
Shilpa CDMO Invests $50 Million to Expand Peptide Manufacturing Capacity in India
Why the pharmaceutical CDMO India segment is racing into peptides: Shilpa’s $50 million plan, what is set for December 2026 and what is undisclosed.
Alembic Pharmaceuticals Q2 FY27 Profit Jumps 81% on Strong US Business
Why the Alembic US business drove Q2 FY27: formulations up 77%, margins up 520 bps and the question of whether the surge can last.
Apollo Hospitals Q2 FY27 Results: Net Profit Rises 32% as Revenue Grows 23%
Why Apollo Hospitals revenue rose 23% in Q2 FY27, how profit and occupancy compare, and what the 5,800-bed plan means for margins and returns.
NHS Launches World-First Multi-Cancer Blood Test Trial Across 200 GP Practices
Why early cancer detection is a market test case: the NHS STRIDE trial, £8.49m public funding and a diagnostics sector Acumen sizes at USD 142.3bn.
Edwards Lifesciences’ PASCAL System Shows Positive One-Year Results in CLASP II TR Trial
Why structural heart devices matter for Edwards: CLASP II TR data on PASCAL and an FDA approval the company reports, plus the safety questions analysts ask.
Boston Scientific’s SIMPLAAFY Trial Reports Positive Results for WATCHMAN FLX Pro Post-Implant Treatment
Why Boston Scientific cardiovascular devices stay in focus: SIMPLAAFY data on WATCHMAN FLX Pro, what is investigational, and what the company has not said.
Teva and Samsung Bioepis Sign US Commercialisation Deal for Two FDA-Approved Biosimilars
What the Teva deal means for the US biosimilars market: two older TNF biosimilars, a staggered rights transfer and financial terms still undisclosed.
Medtronic Reports Significant Blood Pressure Reduction in SPYRAL AFFIRM Renal Denervation Study
Why the Medtronic hypertension device Symplicity Spyral matters after SPYRAL AFFIRM data and an FDA label update that leaves the indication unchanged.
Abbott’s SonicForce Heart Device Achieves 97% Procedural Success in TECTONIC CAD Clinical Trial
Why Abbott cardiovascular devices strategy leans on SonicForce: TECTONIC CAD 30-day data for an investigational coronary IVL system, not yet approved.
